SSG
TNYA icon

Summit Securities Group’s Tenaya Therapeutics TNYA Stock Holding History

Summit Securities Group’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-127
Closed – – 1373
2022
Q3 		$0 Buy
+127
New +$593 ﹤0.01% 1164

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Summit Securities Group's TNYA Position: Q4 2022 in Review

Summit Securities Group sold out of Tenaya Therapeutics (TNYA) in Q4 2022, closing a stake of 127 shares.

Summit Securities Group first reported a position in TNYA in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 68 funds tracked by Wall St. Rank hold TNYA as of Q4 2022.

  • Summit Securities Group reported no remaining Tenaya Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Summit Securities Group sold 127 Tenaya Therapeutics shares in Q4 2022.
  • Summit Securities Group first reported a position in Tenaya Therapeutics in Q3 2022 and held it in 1 quarter.
  • Summit Securities Group's Tenaya Therapeutics position peaked at $0 in Q3 2022.
  • 68 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q4 2022.

Based on Summit Securities Group's 13F filing for Q4 2022, filed 13 Feb 2023.